The American Society of Clinical Oncology (ASCO) has been fighting cancer for more than 50 years. The founding professionals recognized the need for a separate medical group for issues unique to clinical oncology. ASCO’s original physician members helped create a new blueprint that outlined the future of cancer care.
The ASCO of today continues to lead the “drive to improve cancer care.” It is a nonprofit, mission-based organization that is comprised of 35,000 oncology professionals. Many of its members are leaders in their respective fields. ASCO has the trust of the cancer community. It provides primary daily care for cancer patients and spearheads the search for new cancer cures.
A cutting-edge HIT platform
The ASCO Institute for Quality is taking modern cancer care to the next level with CancerLinQ. CancerLinQ is a state-of-the-art health information technology (HIT) platform. It uses the power of Big Data to deliver high-quality care to cancer patients and survivors. CancerLinQ is set to revolutionize how doctors care for individuals with cancer.
Clinical oncology trials currently allow researchers and healthcare professionals to examine only three percent of the total patients who suffer from a specific disease or ailment. CancerLinQ will allow clinicians to move beyond this three percent. They will learn from all cancer patients who undergo diagnosis and/or treatment. CancerLinQ facilitates this learning by providing access to the remaining 97% of patient data; data that was locked away in unconnected electronic health record (EHR) files and servers.
CancerLinQ will help oncologists deliver significant healthcare improvements to cancer patients. It will do this by harnessing the power of Big Data analytics. This innovative HIT platform will provide real-time provider quality feedback based on aggregated reports. It will also help physicians choose the right therapy for their patients. Physicians can make more informed choices based on clinical guidelines and similar patient experiences. And, last, it will analyze real-world cancer care data, as well as organize it. These analytical capabilities are designed to uncover hidden trends that can improve care. The ASCO Institute for Quality explains this phenomenon: “Powerful analytic tools will reveal new, previously unseen patterns in patient characteristics, treatments, and outcomes that can lead to improvements in care.”
The ASCO Institute for Quality reports that CancerLinQ’s development is “well underway.” When completed, CancerLinQ will help ASCO in many ways. It will allow them to “learn from each of the millions of individual patients living with cancer nationwide.” And thus “improve the quality and value of cancer care for all.”
CancerLinQ creates smart reports for special patient populations and genomic types. It also measures performance to offer treatment insights. Physicians can use CancerLinQ’s tools to guide their practice toward its established goals. CancerLinQ is dedicated to maintaining exceptional data quality while adhering to strict patient privacy policies.
The Wall Street Journal recently completed a report on ASCO’s innovative HIT platform. “CancerLinQ reflects growing expectations that information gleaned from huge clinical databases can speed learning about benefits and harms of treatments, support efforts to improve quality of care, and hasten development of new medicines.” As CNN reported: “Shoppers have Amazon. Students have Google. Oncologists will have CancerLinQ.”
Learn more about Digital Transformation for Healthcare here.